2024-07-03 11:00:15 ET
Summary
- Merck offers strong forward earnings growth trends and a compelling current valuation, making it a GARP play with a high yield.
- The health care sector trades at an 18.9 forward earnings multiple, below that of the broader market.
- Merck's strong quarterly results, focus on new launches, and solid outlook make it a buy with the potential for double-digit growth in the coming years.
- I highlight key price levels to monitor ahead of earnings due out later this month.
Merck (MRK) is one of the increasingly rare companies that boasts both strong forward earnings growth trends and a compelling current valuation. Call it a GARP play, but investors also can bank on a high yield with this health care sector stock. I have a buy rating on the $324 billion market cap company. ...
Read the full article on Seeking Alpha
For further details see:
Merck: Among The Best Health Care GARP Plays Today